-
Product Insights
Keratoconjunctivitis - Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...
-
Product Insights
Keratoconjunctivitis Sicca (Dry Eye) - Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...
-
Product Insights
Retinitis Pigmentosa (Retinitis) - Drugs In Development, 2024
Empower your strategies with our Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2024 report and make more profitable business decisions. Retinitis pigmentosa refers to a group of diseases that cause a slow but progressive loss of vision. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa (Retinitis) drugs in development market research report provide comprehensive information on...
-
Product Insights
Dry (Atrophic) Macular Degeneration - Drugs In Development, 2024
Empower your strategies with our Dry (Atrophic) Macular Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Dry (atrophic) macular degeneration is a common eye disorder affecting the macula, the central part of the retina responsible for sharp, central vision. It's characterized by the gradual deterioration of light-sensitive cells in the macula. Symptoms include blurred central vision, difficulty seeing fine details, and in later stages, the presence of drusen (yellow deposits) in the retina. Dry AMD typically...
-
Product Insights
Uveitis - Drugs In Development, 2024
Empower your strategies with our Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. The predisposing factors...
-
Product Insights
Retinal Degeneration - Drugs In Development, 2024
Empower your strategies with our Retinal Degeneration – Drugs In Development, 2024 report and make more profitable business decisions. Retinal degeneration refers to a group of diseases that cause progressive damage to the cells of the retina, the light-sensitive tissue at the back of the eye crucial for vision. These conditions lead to a gradual loss of vision, which can range from mild to severe and can eventually result in blindness. There are several types of retinal degenerative diseases, including: Retinitis...
-
Product Insights
Conjunctivitis - Drugs In Development, 2024
Empower your strategies with our Conjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Conjunctivitis, commonly known as "pink eye", refers to inflammation of the conjunctiva, the thin, transparent layer covering the white part of the eye and the inner surface of the eyelids. This condition can be caused by various factors, including infections, allergies, or irritants. Viral conjunctivitis is typically caused by viruses associated with the common cold; it is highly contagious and often spreads through...
-
Product Insights
Geographic Atrophy - Drugs In Development, 2024
Empower your strategies with our Geographic Atrophy – Drugs In Development, 2024 report and make more profitable business decisions. Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), a progressive eye condition affecting the macula, the central part of the retina responsible for detailed central vision. GA specifically refers to a severe and advanced stage of dry AMD. GA is characterized by the gradual degeneration and death of cells in the macula, leading to the formation of sharply...
-
Product Insights
Open-Angle Glaucoma - Drugs In Development, 2024
Empower your strategies with our Open-Angle Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Open-angle glaucoma is a chronic eye condition characterized by increased intraocular pressure (IOP) that damages the optic nerve, leading to gradual and irreversible vision loss. It is the most common form of glaucoma and develops slowly over time, often without noticeable symptoms in the early stages. In open-angle glaucoma, the drainage system within the eye becomes less efficient over time, leading to...
-
Product Insights
Ocular Hypertension - Drugs In Development, 2024
Empower your strategies with our Ocular Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea, and bleeding at...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.